Brokerages Anticipate Heat Biologics Inc (NASDAQ:HTBX) Will Announce Earnings of -$0.15 Per Share

Share on StockTwits

Analysts expect Heat Biologics Inc (NASDAQ:HTBX) to report ($0.15) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Heat Biologics’ earnings. Heat Biologics also posted earnings per share of ($0.15) in the same quarter last year. The business is scheduled to announce its next quarterly earnings report on Thursday, March 26th.

According to Zacks, analysts expect that Heat Biologics will report full-year earnings of ($0.61) per share for the current fiscal year. For the next financial year, analysts anticipate that the company will report earnings of ($0.61) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Heat Biologics.

A hedge fund recently raised its stake in Heat Biologics stock. Vanguard Group Inc. boosted its holdings in shares of Heat Biologics Inc (NASDAQ:HTBX) by 6.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,327,660 shares of the biopharmaceutical company’s stock after acquiring an additional 84,400 shares during the quarter. Vanguard Group Inc. owned 3.90% of Heat Biologics worth $909,000 at the end of the most recent quarter. 4.93% of the stock is owned by institutional investors.

HTBX remained flat at $$0.48 during trading on Tuesday. 147,372 shares of the company’s stock were exchanged, compared to its average volume of 700,618. Heat Biologics has a 52-week low of $0.35 and a 52-week high of $1.80. The company has a quick ratio of 3.29, a current ratio of 3.29 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $16.39 million, a PE ratio of -0.53 and a beta of 1.77. The stock has a 50 day moving average price of $0.45 and a two-hundred day moving average price of $0.59.

About Heat Biologics

Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.

Recommended Story: Price to Earnings Ratio (PE)

Get a free copy of the Zacks research report on Heat Biologics (HTBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.